New Commercial Partnership in Australia

About this update from Probiotix Health Plc

20 October 2025   ProBiotix Health plc ("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")   New Commercial Partnership in Australia   ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a commercial partnership with Australia based Wellizen.   Wellizen is an innovation-driven wellness consumer brand company with a focus on health solutions in nutrition, microbiome and lifestyle wellness. Headquartered in Sydney, Australia, it has operations across New Zealand, Southeast Asia, North America and the Middle East. Wellizen has successfully established its consumer brand THERO NOMIC ® as a market leader in the precision biotic supplement consumer space.    ProBiotix will supply LP LDL ® for local manufacturing of a new innovative dietary supplement capsule product targeting cardiometabolic health: Tri-Biotic Cardi-Flo , introduced under the THERO NOMIC ® brand. The commercial rollout will take place in October this year, with an initial launch in Singapore through Wellizen's direct retail consumer e-commerce platform, followed by a late October direct to consumer launch in Australia. Additional market entries across New Zealand, Southeast Asia and other Asian markets are planned for the coming months as part of a phased regional expansion strategy. Potential future channels include business to business pharmacy distribution across Australia, New Zealand, Dubai, and the wider Middle East.   The nutraceutical segment addressing cardiometabolic health is experiencing strong growth across all the target regions, with market expansion rates of 8-10% annually* , driven by rising lifestyle-related health concerns and demand for clinically supported, science-based preventive product solutions.   Steen Andersen, CEO of ProBiotix, commented : "The use of our clinically proven LP LDL ® by Wellizen to complement their existing THERO NOMIC ® consumer product range, marks a significant step for ProBiotix. It further validates the increasing application of our innovative technology to target those suffering with high cholesterol, and we are very excited about its future sales potential.   " High cholesterol affects an estimated 30-48% of adults in Southeast Asia, around 30% in Australia, and nearly one-third of adults across the Middle East, representing a major and fast-growing cardiometabolic health challenge globally**."   Julie Chen, Head of R&D of THERO NOMIC ® , added: "We're excited to launch THERO NOMIC ® Cardi-Flo as part of our ongoing mission to deliver science-backed solutions that address health at its root through the gut.   "This product showcases our innovative Tribiotic® platform and features LP LDL ® , a clinically studied probiotic strain with proven benefits for cardiometabolic health. Our partnership with ProBiotix reflects a shared commitment to advancing microbiome science, and we are confident Cardi-Flo will bring meaningful impact to consumers seeking natural, evidence-based support for heart health."   *Source: Precedence Research - Asia Pacific Cardiovascular Health Supplements Market (2025-2034) , Grand View Research - Asia Pacific Cardiovascular Health Supplements Market Size & Outlook (2025-2030) **Source: Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region" by Lee et al., 2021 and Australian Bureau of Statistics (ABS) - National Health Measures Survey, 2022-24   For further information, please contact:   ProBiotix Health plc https://probiotixhealth-ir.com/   [email protected] Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations   Peterhouse Capital Limited Aquis Corporate Adviser and Broker       Mark Anwyl Duncan Vasey   Tel: 020 7469 0930   This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.   Notes to Editors:   ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.   The Company has a singular approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.  

View stock analysis, news, and events for Probiotix Health Plc